Medical Minds Blog
Featured
Low titer group O whole blood (LTOWB) is increasingly being used for prehospital transfusion, and, therefore, many partnering hospitals are finding new ways to utilize this valuable resource.
The FDA’s approval of Kresladi (marnetegragene autoemcel) marks a major milestone for pediatric patients with severe Leukocyte Adhesion Deficiency Type I (LAD-I), a rare immune disorder that affects 1 in 1 million people each year. It is the first FDA-approved gene therapy for this condition.
Maintaining a safe, readily available blood supply that mirrors the full scope of our community is a vital responsibility for Carter BloodCare. We are dedicated to increasing awareness of this integral mission to best support the health and well-being of all patients across North, Central and East Texas.
This transition marks a pivotal moment in the organization's commitment to providing the highest-quality blood products to patients while minimizing hands-on manual steps, cutting processing time, increasing efficiency, preventing errors and reducing waste, says Barbara Bryant, M.D., President and CEO of Carter BloodCare.
This blog discusses neonatal transfusion with red blood cells stored in additive solutions.